Composition for suppressing intestinal succinic acid content and food and drink containing the same

Abstract

To provide a novel functional material that effectively reduces the intestinal production of succinic acid while maintaining the intestinal production levels of short-chain fatty acids such as acetic acid, propionic acid, or butyric acid.SOLUTION: A composition for reducing intestinal succinic acid levels contains Lactococcus lactis subsp. cremoris. The composition may be consumed with indigestible oligosaccharides and / or dietary fibers. The composition may be used to increase the intestinal production levels of one or more short-chain fatty acids selected from the group consisting of acetic acid, propionic acid, and butyric acid while reducing the intestinal succinic acid levels. The composition may be foods and beverages, additive materials for foods and beverages, pharmaceuticals, additive materials for pharmaceuticals, animal feed, or additive materials for animal feed.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a functional material that has the effect of suppressing the amount of succinic acid in the intestines. [Background technology]

[0002] Short-chain fatty acids produced by intestinal bacteria include acetic acid, propionic acid, and butyric acid. These organic acids are absorbed in the large intestine and serve as an important energy source for the host. For example, in pigs, these organic acids account for 30% of the energy absorbed. Furthermore, butyric acid is used as an energy source for the proliferation of mucosal epithelial cells, and has been reported to promote epithelial cell division, contribute to mucosal thickening, and even promote large intestinal motility (see Non-Patent Documents 1, 2, and 3).

[0003] On the other hand, succinic acid, a type of short-chain fatty acid, is produced in the intestine at a rate that is high enough to penetrate the body. pressure It is known to be a cause of chronic diarrhea (see Non-Patent Documents 4 and 5). [Prior art documents] [Non-patent literature]

[0004] [Non-Patent Document 1] Shimotoyodome, a., Meguro, S., Hase, T., Tokimitsu, I., Sakata, T. (2000) Short chain fatty acids but not lactate or succinate stimulate mucus release in the rat colon. Comp. Biochem. Physiol. 125(4):pp.525-531. [Non-patent document 2] Sakata, T. (1997) Influence of short-chain fatty acids on intestinal growth and functions. In:Dietary Fiber in Health and disease (Kritchevsky, D. and Bonfield, C. eds.), pp. 191-199. Plenum Press, New York, NY.

Non-Patent Document 3

Non-Patent Document 4

Non-Patent Document 5

[0005] According to the research of the present inventors, when the amount of short-chain fatty acids produced in the intestine such as acetic acid, propionic acid, and butyric acid increases, an increase in succinic acid, a type of short-chain fatty acid, is observed, which leads to permeation. pressure It is thought that this may be a cause of diarrhea.

[0006] Therefore, an object of the present invention is to provide a new functional material that has the effect of suppressing the production of succinic acid in the intestine while maintaining the amount of short-chain fatty acids such as acetic acid, propionic acid, and butyric acid produced in the intestine. [Means for solving the problem]

[0007] As a result of various studies conducted to achieve the above-mentioned objective, the inventors discovered that Lactobacillus cremoris, a lactic acid bacterium known to be derived from Caspian Sea yogurt, has the effect of suppressing the amount of succinic acid in the intestines while maintaining the amount of short-chain fatty acids produced in the intestines, such as acetic acid, propionic acid, and butyric acid, and thus completed the present invention.

[0008] That is, the present invention provides a composition for suppressing the amount of succinic acid in the intestine, which comprises Lactobacillus cremoris.

[0009] The composition for reducing the amount of succinic acid in the intestines according to the present invention is preferably used by being ingested together with indigestible oligosaccharides and / or dietary fiber.

[0010] The composition for suppressing the amount of succinic acid in the intestines of the present invention is preferably intended to increase the amount of one or more short-chain fatty acids selected from the group consisting of acetic acid, propionic acid, and butyric acid produced in the intestines while suppressing the amount of succinic acid in the intestines.

[0011] The composition for suppressing the amount of succinic acid in the intestines according to the present invention has the effect of improving the intestinal environment and / or penetrating pressure It is preferably for the suppression of sexually transmitted diarrhea.

[0012] In the composition for suppressing intestinal succinic acid content according to the present invention, the Lactobacillus cremoris is preferably killed.

[0013] The composition for reducing the amount of succinic acid in the intestine according to the present invention preferably contains kestose as the indigestible oligosaccharide.

[0014] The composition for reducing the amount of succinic acid in the intestine according to the present invention preferably contains resistant starch as the dietary fiber.

[0015] The composition for suppressing intestinal succinic acid content according to the present invention can be a food or drink, a food or drink additive material, a pharmaceutical product, a pharmaceutical additive material, animal feed, or an animal feed additive material.

[0016] On the other hand, from another aspect, the present invention provides a food or drink containing the above-mentioned composition for suppressing the amount of succinic acid in the intestine. [Effects of the Invention]

[0017] According to the present invention, a new functional material can be provided that utilizes Lactobacillus cremoris and has the effect of suppressing the amount of succinic acid in the intestine while maintaining the amount of short-chain fatty acids produced in the intestine, such as acetic acid, propionic acid, and butyric acid. [Brief explanation of the drawings]

[0018] [Figure 1] This is a graph showing the results of an investigation into the effect of oral administration of lactic acid bacteria on the amount of succinic acid in the intestines in Test Example 1, and shows the results of measuring the succinic acid concentration in the cecal contents of rats that were administered Lactobacillus faecalis or Lactobacillus cremoris as test samples for 7 days. [Figure 2] This is a graph showing the results of an investigation into the effect of oral administration of Lactobacillus cremoris and indigestible oligosaccharides or dietary fiber on the amount of succinic acid in the intestine in Test Example 2, and shows the results of measuring the succinic acid concentration in the cecal contents of rats that were administered Lactobacillus cremoris and indigestible oligosaccharides (kestose) or dietary fiber (resistant starch) as test samples for 7 days. [Figure 3] This is a graph showing the results of an investigation into the effect of oral administration of Lactobacillus cremoris and indigestible oligosaccharides on the intestinal production of short-chain fatty acids, including succinic acid, in Test Example 3. This graph shows the results of measuring the concentration of short-chain fatty acids, including succinic acid, in the cecal contents of rats that were administered indigestible oligosaccharides (kestose) alone or in combination with Lactobacillus cremoris as a test sample for 7 days. [Figure 4] This is a graph showing the results of an investigation into the effect of oral administration of Lactobacillus cremoris and dietary fiber on the intestinal production of short-chain fatty acids such as butyric acid in Test Example 4.The graph shows the results of measuring the concentrations of short-chain fatty acids such as acetic acid, propionic acid, and butyric acid in the cecal contents of rats that were administered dietary fiber (resistant starch) in combination with Lactobacillus cremoris as a test sample for 7 days. DETAILED DESCRIPTION OF THE INVENTION

[0019] The Lactococcus cremoris used in the present invention is known as a lactic acid bacterium derived from Caspian Sea yogurt, and its scientific name is Lactococcus lactis subsp. cremoris. Examples include the Lactococcus lactis subsp. cremoris Flora aid strain (accession number: NITE BP-03259), which is deposited at the Patent Microorganisms Depositary (NPMD) of the Biotechnology Center, National Institute of Technology and Evaluation.

[0020] Cultivation of Lactobacillus cremoris and maintenance of the bacterial cells can be carried out by well-known techniques. For example, media suitable for culturing lactic acid bacteria include skim milk powder medium, or liquid media containing yeast extract, peptone, meat extract, salts, minerals, etc. Commercially available media include "MRS Bouillon MERCK" (trade name, Chemicals Co.) and "Difco Lactobacilli MRS Broth" (trade name, Nippon Becton Dickinson Co., Ltd.), and such commercially available media may also be used.

[0021] Generally, lactic acid bacteria can be cultured by, for example, standing still, without any particular limitation. Alternatively, to prevent a decrease in pH due to metabolic products of lactic acid bacteria (such as lactic acid), culture (neutral culture) may be performed while adjusting the pH by adding an alkaline agent to the medium. In this case, the alkaline agent to be added may be, for example, an aqueous solution of sodium hydroxide, potassium hydroxide, calcium hydroxide, or the like, or ammonia. The pH during culture may be in the range of 5.0 to 7.5, or may be in the range of 6.0 to 7.0, and is preferably adjusted and maintained at that pH. pH adjustment may be performed manually, but it is simpler and more accurate if an automatic pH control device (pH stat) is used.

[0022] In the present invention, a bacterial cell concentrate in which Lactobacillus cremoris is concentrated may be prepared from the culture solution, or, preferably, an excipient may be added and then freeze-dried. The bacterial cell concentrate can be prepared by directly concentrating the culture solution, but preferably, the bacterial cells are collected by means of centrifugation or filtration, washed with purified water, or the like, and then suspended in purified water to a predetermined bacterial cell concentration. The content of Lactobacillus cremoris cells in 100% by mass of the bacterial cell concentrate may be in the range of 0.1 to 30% by mass, 0.5 to 20% by mass, or 1 to 10% by mass, calculated as dry bacterial cells.

[0023] The bacterial cell concentrate may also contain an excipient. This makes it easier for the bacterial cell to maintain its viable properties after reconstitution with water, even after freezing or lyophilization. In another embodiment, when the bacterial cells are pulverized and dispersed, reagglomeration of the resulting lactic acid bacteria powder can be prevented. The content of the excipient may be in the range of 10 to 99% by mass, 20 to 95% by mass, or 50 to 90% by mass, calculated on a dry basis.

[0024] The excipient is not particularly limited, and examples thereof include dextrin; maltodextrin; xanthan gum; sugar alcohols such as lactitol, maltitol, mannitol, sorbitol, and xylitol; sugars such as dextrose, fructose, glucose, lactose, and sucrose; and organic acids such as adipic acid, citric acid, fumaric acid, glutaric acid, malic acid, succinic acid, and tartaric acid.

[0025] In the present invention, Lactobacillus cremoris may be subjected to a crushing and dispersion treatment. For example, the above-mentioned concentrated bacterial cell solution can be crushed and dispersed using means such as stirring, a mixer, a homogenizer, a ball mill, a bead mill, a jet mill, or a generator.

[0026] The Lactobacillus cremoris used in the present invention may be live cells. In this case, it is preferable to use live cells that have been cultured, added with the above-mentioned excipients, and then freeze-dried to prepare a powder. This makes it convenient to provide live Lactobacillus cremoris in the form of capsules, granules, yogurt, etc.

[0027] On the other hand, killed Lactobacillus cremoris cells may be used. For example, the concentrated cell solution may be heat-treated before or after the step of pulverizing and dispersing the concentrated cell solution. Furthermore, the concentrated cell solution may be dried and powdered after the step of pulverizing and dispersing the concentrated cell solution. Examples of methods for drying and powdering include freeze-drying, reduced-pressure spray drying, and spray drying using hot air. Note that spray drying using hot air usually kills the lactic acid bacteria, and killed cells can be obtained.

[0028] The composition for suppressing the amount of succinic acid in the intestines of the present invention uses Lactobacillus cremoris or a processed product thereof that can be prepared as described above, and is administered to humans or non-human animals to suppress the amount of succinic acid in the intestines. In particular, the composition is intended to suppress the amount of succinic acid in the intestines while maintaining the amount of short-chain fatty acids produced in the intestines, such as acetic acid, propionic acid, and butyric acid. Typically, the composition is used for, for example, improving the intestinal environment or increasing the amount of permeation. pressure The method of administration is not particularly limited, but oral administration is preferred, for example.

[0029] The dosage of the composition for suppressing intestinal succinic acid content according to the present invention may be appropriately determined depending on the health condition and age of the subject, the degree of effect of suppressing intestinal succinic acid content that is required, etc. Typically, the intake amount of the Lactobacillus cremoris cells or a processed product thereof, calculated on a dry matter basis, may be in the range of 0.001 mg to 100 mg / day / kg body weight, 0.01 mg to 20 mg / day / kg body weight, or 0.1 mg to 10 mg / day / kg body weight.

[0030] The composition for suppressing intestinal succinic acid content according to the present invention may contain cells or processed products of microorganisms other than those derived from Lactobacillus cremoris, as long as the effects of the present invention are not impaired. Examples of such cells include lactic acid bacteria other than Lactobacillus cremoris, bifidobacteria, Bacillus subtilis, butyric acid bacteria, yeast, koji mold, actinomycetes, etc.

[0031] The composition for suppressing intestinal succinic acid levels according to the present invention may be provided as a food or beverage for suppressing intestinal succinic acid levels. That is, the Lactobacillus cremoris cells or a processed product thereof may be used as such or combined with other food or beverage ingredients to produce a food or beverage. Examples of food or beverage ingredients to be combined with the Lactobacillus cremoris cells or a processed product thereof include various carbohydrates, emulsifiers, sweeteners, acidulants, fruit juice, flavors, etc. More specifically, examples include sugars such as glucose, sucrose, fructose, and honey; sugar alcohols such as sorbitol, xylitol, erythritol, lactitol, and palatinit; and emulsifiers such as sucrose fatty acid esters, glycerin sugar fatty acid esters, and lecithin. Other examples include various vitamins such as vitamin A, vitamin B, vitamin C, and vitamin E; herb extracts; grain ingredients; vegetable ingredients; and dairy ingredients.

[0032] Examples of foods and beverages include, but are not limited to, confectioneries such as cookies, rice crackers, jellies, sweet bean jelly, yogurt, and manju, as well as soft drinks, nutritional drinks, and soups. Other examples of foods and beverages include health foods, supplements, foods for specified health uses, and foods with functional claims for suppressing intestinal succinic acid levels, which may be provided in the form of tablets, granules, powders, capsules, drinks, jellies, and the like.

[0033] On the other hand, the composition for suppressing the amount of succinic acid in the intestines according to the present invention may be provided as a food and drink additive material for suppressing the amount of succinic acid in the intestines, which is used as an additive to the above-mentioned foods and drinks.

[0034] The composition for suppressing intestinal succinic acid levels according to the present invention may be provided as a pharmaceutical for suppressing intestinal succinic acid levels. That is, the Lactobacillus cremoris cells or a processed product thereof may be used as is or combined with other pharmaceutical ingredients to form a pharmaceutical composition. There are no particular limitations on the other pharmaceutical ingredients to be combined with the Lactobacillus cremoris cells or a processed product thereof. If necessary, a pharmaceutically acceptable base or carrier may be added, and the composition may be formulated into, for example, tablets, granules, capsules, pills, powders, liquids, powders, jelly-like agents, or candies by known formulation methods, and used as an oral preparation.

[0035] On the other hand, the composition for suppressing the amount of succinic acid in the intestines according to the present invention may be used as an additive to such pharmaceuticals, and may be a pharmaceutical additive material for suppressing the amount of succinic acid in the intestines.

[0036] The composition for suppressing the amount of succinic acid in the intestines of the present invention may be an animal feed for suppressing the amount of succinic acid in the intestines. That is, for example, the Lactobacillus cremoris cells or a processed product thereof may be used as is or in combination with other animal feed ingredients to form a composition for animal feed. For example, it may be used in animal feed for livestock, racehorses, ornamental animals, pets, etc.

[0037] On the other hand, the composition for suppressing the amount of succinic acid in the intestines according to the present invention may be used as an additive to such animal feed, and may be an animal feed additive material for suppressing the amount of succinic acid in the intestines.

[0038] In the composition for suppressing intestinal succinic acid content according to the present invention, the content of the bacterial cells or a processed product thereof may be appropriately determined in consideration of the relationship between the amount used and the effective dose when it is in various forms. Typically, the content of the bacterial cells or a processed product thereof may be in the range of 0.1 to 100% by mass, 1 to 50% by mass, or 10 to 30% by mass, calculated as a dry matter. Furthermore, the content calculated as the number of bacterial cells may be 1 x 10 5 ~1×10 8 cells / g, and may range from 1 x 10 6 ~5×10 7cells / g, and may range from 1 x 10 7 ~3.3×10 7 The cell density may be in the range of cells / g.

[0039] In any non-limiting embodiment of the present invention, the composition for suppressing the amount of succinic acid in the intestines, which contains the above-mentioned Lactobacillus cremoris, may be ingested together with indigestible oligosaccharides and / or dietary fiber. In this way, the ingestion of indigestible oligosaccharides and / or dietary fiber can promote the production of short-chain fatty acids in the intestines, without increasing the amount of succinic acid, a type of short-chain fatty acid, produced in the intestines. Therefore, this allows the infiltration pressure It is possible to enjoy the benefits of ingesting indigestible oligosaccharides and / or dietary fiber while suppressing the amount of succinic acid in the intestine, which is a cause of chronic diarrhea, etc. In this case, the short-chain fatty acids in the intestine that can be promoted by ingesting indigestible oligosaccharides and / or dietary fiber specifically include acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid, caproic acid, etc., and more typically acetic acid, propionic acid, butyric acid, etc.

[0040] In the above-mentioned embodiment, the indigestible oligosaccharide used in the present invention is not particularly limited, and examples thereof include galactooligosaccharides, fructooligosaccharides, soybean oligosaccharides, kestose, raffinose, isomaltooligosaccharides, etc. Kestose is particularly preferred.

[0041] In the above embodiment, the dietary fiber used in the present invention is not particularly limited, and examples thereof include high-amylose cornstarch, pectin, chitin, glucomannan, alginic acid, β-glucan, inulin, indigestible dextrin, carrageenan, fucoidan, guar gum, xanthan gum, gellan gum, pectin, sodium alginate, crystalline cellulose, etc. High-amylose cornstarch is particularly preferred.

[0042] Commercially available high-amylose cornstarch products include, for example, J-Oil Mills' "Amylo Fiber SH," Ingredion's "Hi-Maize 1043," Nippon Shokuhin Kako's "Roadstar," and Sanwa Starch's "Amylogel HB-450." Alternatively, cornstarch may be used that has been subjected to heat treatment or other methods to increase its dietary fiber content, as described in, for example, JP-A-10-195104 and WO 2008 / 155892. For example, cornstarch with a dietary fiber content of 40% by mass or more is preferred, with cornstarch having a dietary fiber content of 50% by mass or more being more preferred, and cornstarch having a dietary fiber content of 60% by mass or more being even more preferred. The dietary fiber content can be measured by the "enzyme-gravimetric method" or "enzyme-HPLC method" described in the Food Labeling Act.

[0043] The water-soluble, indigestible oligosaccharides and dietary fibers exemplified above effectively serve as nutrient sources for intestinal bacteria in the intestine, and are therefore highly effective in promoting the production of intestinal short-chain fatty acids.

[0044] In the present invention, when Lactobacillus cremoris is used by being ingested together with indigestible oligosaccharides and / or dietary fiber, as in the above-mentioned embodiment, the above-mentioned Lactobacillus cremoris may be ingested in the form of a separate composition, separate from the indigestible oligosaccharides and / or dietary fiber, or may be ingested in the form of a single composition containing Lactobacillus cremoris together with the indigestible oligosaccharides and / or dietary fiber.

[0045] When the composition for suppressing intestinal succinic acid content according to the present invention is formulated as a single agent in the above-mentioned embodiment, the contents of the Lactobacillus cremoris and the indigestible oligosaccharides and / or dietary fiber may be appropriately determined in various forms, taking into consideration the relationship between the amount used and the effective dose. Typically, the content of the bacterial cells or a processed product thereof, calculated on a dry matter basis, may be in the range of 0.1 to 99.9% by mass, 1 to 50% by mass, or 10 to 30% by mass. Furthermore, the content calculated on a bacterial cell count basis may be 1 x 10 5 ~1×10 8cells / g, and may range from 1 x 10 6 ~5×10 7 cells / g, and may range from 1 x 10 7 ~3.3×10 7 The content of indigestible oligosaccharides and / or dietary fiber in terms of dry matter may be in the range of 0.1 to 99.9% by mass, 1 to 50% by mass, or 10 to 30% by mass. [Example]

[0046] The present invention will be specifically explained below with reference to examples, but these examples are not intended to limit the scope of the present invention.

[0047] <Test Example 1> We investigated the effect of oral administration of lactic acid bacteria on intestinal succinic acid levels. Specifically, the test was conducted by orally administering killed cells of lactic acid bacteria to rats. Five rats (Crlj:WI (Wister), male, 8 weeks old) were used as test animals for each test group. Lactococcus lactis subsp. cremoris (Flora Aid) (Accession Number: NITE BP-03259) or Enterococcus faecalis were used as test samples, and killed cells prepared by heat treatment were used for both.

[0048] The dosage form of each lactic acid bacterium was 2.8 x 10 heat-treated Lactobacillus cremoris. 10 Physiological saline containing 3.2 × 10 cells / mL of heat-treated Lactobacillus faecalis cells was prepared and administered orally at a dose of 1 mL once daily for 7 days. 10 Physiological saline containing lactic acid bacteria at a concentration of 1000 cells / mL was prepared and orally administered to rats in the same manner. As a control, the same volume of physiological saline without lactic acid bacteria was orally administered.

[0049] On the seventh day after the start of administration, the animals were dissected and the cecal contents were collected, and the succinic acid concentration in the cecal contents was analyzed. Succinic acid analysis was performed according to the method described in "Effect of pH on the Fermentation of Indigestible Oligosaccharides by Porcine Cecal Contents," by Kazunari Ushida and Takashi Sakata, Nihon Chiku Kaiho (1998), 69(2): pp. 100-107. Specifically, the samples were pretreated as follows and then analyzed by ion exclusion chromatography.

[0050] (Sample pretreatment) A 0.1 mL aliquot of the cecal contents was suspended in 0.2 mL of distilled water, 0.03 mL of 12% perchloric acid was added, and the suspension was left on ice for 10 minutes. Proteins were precipitated by centrifugation, and the supernatant was filtered through a 0.45 μm filter. 100 μL of the sample was used for analysis.

[0051] (Ion Exclusion Chromatography Analysis) Shim-Pack SCR-102H (H-type sulfo group, particle size 7 μm, length 300 mm x inner diameter 8 mm, Shimadzu Corporation) Column temperature: 40℃ Mobile phase: HPLC-grade distilled water containing 5 mM p-toluenesulfonic acid Post-column reaction phase: 5 mM p-toluenesulfonic acid, 20 mM Bis-tris, 100 μM EDTA in HPLC-grade distilled water Solvent flow rate: 0.8 mL / min Detector: Waters 431 conductivity meter (detection base voltage: 2000 mV, detection sensitivity: 0.01) System controller: ChromNAV (JASCO Corporation) Component identification: Analyze STDs using the above system and calculate the concentration in the sample.

[0052] The results are shown in Figure 1.

[0053] As a result, as shown in Figure 1, rats administered Lactobacillus faecalis showed intestinal succinic acid levels equivalent to those of the control group administered saline, whereas rats administered Lactobacillus cremoris showed a significant decrease in intestinal succinic acid levels.

[0054] <Test Example 2> The effects of oral administration of Lactobacillus cremoris and indigestible oligosaccharides or dietary fiber on intestinal succinic acid levels were investigated. Specifically, animal studies were conducted as in Test Example 1. When Lactobacillus cremoris was administered as a test sample, it was administered in the same manner as in Test Example 1 using an oral tube. When indigestible oligosaccharides or dietary fiber were administered as a test sample, kestose (trade name "iKes75", manufactured by Itochu Sugar Refining Co., Ltd.) was used as the indigestible oligosaccharide, or resistant starch (trade name "Hi-Maize", manufactured by Ingredion Japan Co., Ltd.) was used as the dietary fiber. These were added to rat feed (standard purified diet AIN-93M, manufactured by CLEA Japan Inc.) at a concentration of 5% by mass and given ad libitum.

[0055] On the seventh day after the start of administration, the rats were dissected to collect the cecal contents, and the succinic acid concentration in the cecal contents was analyzed in the same manner as in Test Example 1.

[0056] The results are shown in FIG. 2 together with the results for the "control" and "Lactobacillus cremoris" obtained in Test Example 1.

[0057] As a result, as shown in Figure 2, the test groups administered kestose (indicated by "KES" in the figure) or resistant starch (indicated by "RS" in the figure) tended to have an increased amount of succinic acid in the intestines compared to the control group administered physiological saline. However, it was revealed that when Lactobacillus cremoris was administered in combination, this tendency for an increase was suppressed.

[0058] <Test Example 3> The effect of oral administration of Lactobacillus cremoris and indigestible oligosaccharides on the intestinal production of short-chain fatty acids, including succinic acid, was investigated. Specifically, animal testing was performed in the same manner as in Test Example 1. When Lactobacillus cremoris was administered as a test sample, it was administered in the same manner as in Test Example 1 using an oral tube. When indigestible oligosaccharides were administered as a test sample, kestose was used as the indigestible oligosaccharide, and it was added to rat feed ("Standard Purified Feed AIN-93M," manufactured by CLEA Japan, Inc.) at a concentration of 5% by mass and given ad libitum.

[0059] On the seventh day after the start of administration, the rats were dissected to collect the cecal contents, and the concentrations of short-chain fatty acids, including succinic acid, in the cecal contents were analyzed in the same manner as in Test Example 1.

[0060] The results are shown in Figure 3.

[0061] As a result, as shown in Figure 3, the test group administered kestose (indicated by "KES" in the figure) tended to have increased intestinal production of succinic acid, propionic acid, and butyric acid compared to the control group administered physiological saline. In contrast, when Lactobacillus cremoris was administered in combination, the increase in succinic acid was suppressed, and the intestinal production of acetic acid, propionic acid, and butyric acid all tended to increase further compared to the test group administered ketose alone.

[0062] <Test Example 4> The effects of oral administration of Lactobacillus cremoris and dietary fiber on the intestinal production of short-chain fatty acids such as acetic acid, propionic acid, and butyric acid were investigated. Specifically, animal testing was performed in the same manner as in Test Example 1, and when Lactobacillus cremoris was administered as a test sample, it was administered in the same manner using an oral tube as in Test Example 1. When dietary fiber was administered as a test sample, resistant starch was used as the dietary fiber, and it was added to rat feed ("Standard Purified Feed AIN-93M", manufactured by CLEA Japan, Inc.) at a concentration of 5% by mass, which was then given ad libitum.

[0063] On the seventh day after the start of administration, the rats were dissected and the cecal contents were collected. In the same manner as in Test Example 1, the concentrations of short-chain fatty acids such as acetic acid, propionic acid, and butyric acid in the cecal contents were analyzed.

[0064] The results are shown in Figure 4.

[0065] As a result, as shown in Figure 4, the test group administered resistant starch (indicated by "RS" in the figure) tended to have increased intestinal production of succinic acid, propionic acid, and butyric acid compared to the control group administered saline.

[0066] [summary] The results of Test Examples 1 to 4 above revealed that Lactobacillus cremoris has the effect of suppressing the amount of succinic acid in the intestines, and that it does not suppress but rather promotes the effect of indigestible oligosaccharides and dietary fiber in increasing the amount of short-chain fatty acids such as acetic acid, propionic acid, and butyric acid in the intestines.

Claims

1. A composition for suppressing intestinal succinic acid content, comprising Lactobacillus cremoris, The composition for suppressing the amount of succinic acid in the intestines, wherein the Lactococcus cremoris is Lactococcus lactis subsp. cremoris Flora aid strain (accession number: NITE ABP-03259).

2. 2. The composition for suppressing the amount of succinic acid in the intestines according to claim 1, which is taken together with indigestible oligosaccharides and / or dietary fiber.

3. 3. The composition for suppressing the amount of succinic acid in the intestines according to claim 1 or 2, which is used for improving the intestinal environment and / or suppressing osmotic diarrhea.

4. The composition for suppressing the amount of succinic acid in the intestines according to claim 1 or 2, wherein the Lactobacillus cremoris is a killed cell.

5. 3. The composition for suppressing the amount of succinic acid in the intestines according to claim 2, wherein the indigestible oligosaccharide contains kestose.

6. 3. The composition for suppressing intestinal succinic acid content according to claim 2, wherein the dietary fiber comprises resistant starch.

7. 3. The composition for suppressing intestinal succinic acid content according to claim 1 or 2, which is a food or drink, a food or drink additive material, a pharmaceutical product, a pharmaceutical additive material, an animal feed, or an animal feed additive material.

Images